Biopharma Should Copy Our Gilead Deal, Says Rising Star Galapagos

‘Standstill’ Guarantees Biotech’s Independence

$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.

Jefferies_Stolpe — Galapagos CEO Onno van de Stolpe at the Jefferies conference in London

Galapagos chief executive Onno van de Stolpe said he and Gilead’s Daniel O’Day toasted their $5.1bn “transformative” research deal with a glass of champagne in New York before they unveiled it to the biopharma world in July.

The alliance was based on their co-developed filgotinib for rheumatoid arthritis, which could claim best-in-class status in the oral JAK inhibitor

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

15 May 2025

• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.